Vision Medicals takes home RMB 100m in Series A



Guangzhou-based Vision Medicals reportedly raised RMB 100 million (USD 14million) via a Series A financing round, co-led by Volcanics Venture and Cash Capital. The proceeds will be utilized to upgrade pathogenic metagenomics products and rapid gene testing diagnostic products, bolster registration inspections and clinical trials for the firm's first pathogenic metagenomics product and help to co-establish a national medical laboratory network as well as collaborations with Class 3A hospitals in China.

Vision Medicals specializes in gene technology and precision medicine, offering IDseq, a pathogen metagenomics platform, and ID-CRISPR, a pathogen CRISPR-based rapid diagnosis platform. The former enables 24-hour delivery of DNA/RNA dual process testing. In addition, the company has a medical laboratory, research and development center and a Good Manufacturing Practice (GMP)-compliant facility covering a total 3,000 sq.m.


Reference:

Related news
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
China-based CanSino Biologics Inc., (06185.HK), a new Hong Kong Stock Exchange (HKSE) entrant, unveiled its financial performance during the first half of 2019, chalking up no revenue thanks to lack of product commercialization, and a RMB 69.68 million (USD 9.8 million) loss, up 35.3% year-on-year (YOY).
Beijing-based AllinMD Orthopedics, describing itself as China’s first eco-enterprise focused on the entire orthopedics industry chain, has reportedly raised USD 100 million (RMB 709.6 million) via Series B financing round.
Ping An Insurance (Group) Co., Ltd, (HKEX: 2318; SSE: 601318) announced that its Ping An Global Voyager Fund led a USD 15 million investment round focused on the US-based Riverain Technologies.
Recent news
A study carried out by investigators at Brazil’s Oswaldo Cruz Foundation (Fiocruz) estimated the coping costs for the caretakers of minors with one of three selected rare diseases.
Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week ruled that all medical products that contain active pharmaceutical ingredients (APIs) that require bioequivalence tests must submit applications for these studies within 180 days.
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) announced that the GEMSTONE-101 cohort study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) CS1001 combined with cisplatin plus fluorouracil (CF) therapy in esophagus squamous cell carcinoma (ESCC) has yielded a 77.8% objective response rate (ORR) with good safety.
Shenzhen Chipscreen Biosciences Co., Ltd, (SH.688321) announced acceptance for review from the National Medical Products Administration (NMPA) in relation to a new drug application (NDA) filed for hypoglycemic drug chiglitazar (Bilessglu).
A draft law presented this week to Peru’s unicameral Congress by the New Peru (Nuevo Perú) minority party would force medics to prescribe generic medicines as a primary choice and originator drugs as a second alternative.
Analytics Snapshot


Analytics Snapshot